By Mill Chart
Last update: Sep 25, 2023
Discover PFIZER INC (NYSE:PFE)—a stock that our stock screener has recognized as a solid dividend pick with strong fundamentals. NYSE:PFE showcases decent financial health and profitability while providing a sustainable dividend. We'll explore the specifics further.
ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:PFE scores a 8 out of 10:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has achieved a 5 out of 10:
ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:PFE, the assigned 8 is noteworthy for profitability:
Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.
Our latest full fundamental report of PFE contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
PFIZER INC
NYSE:PFE (4/26/2024, 7:09:35 PM)
After market: 25.45 +0.05 (+0.2%)25.4
+0.14 (+0.55%)
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
You'll get dividends and more with these great stocks.
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.
CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.
Put your money to work by investing in these three high-quality dividend stocks.
Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.